CENEXA   05419
CENTRO DE ENDOCRINOLOGIA EXPERIMENTAL Y APLICADA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Melatonin exerts benefic effects on the rat model of Metabolic Syndrome and on the normal rat
Autor/es:
SPINEDI E; CARDINALI DP; PAGANO E; GENARO A
Lugar:
Glasgow
Reunión:
Congreso; 26th European Congress on Obesity (ECO) Glasgow, UK, 28 April- 01 May, 2019; 2019
Institución organizadora:
EASO (European Association for the Study of Obesity)
Resumen:
Introduction: Given the worldwide epidemic of Diabetes, Obesity andMetabolic Syndrome (MS), studying possible prevention or attenuationtreatments is mandatory. MS is a multifactorial phenomenom not onlyrelated to an unadequate nutrition and sedentarism, but also to an unbalancedlife style and unnatural light-dark cycles. Prolonged exposure tolight during night and sleep impairment negatively affect many vital processes,as shown by a decreased melatonin production, modified circadianrhythms and oxidative overload. Previous work from our team and othershave shown that melatonin is capable to counteract some of the undesiredmetabolic effects of a high fat diet.Methods: Male Wistar rats fed ad libitum with regular chow and 10% fructosedrinking solution were used as a valid MS experimental model.We established 4 groups: control(C), fructose 10% (F), fructose + melatonin(FM) and melatonin (25 μg/mL drinking solution) (M). We checked MSprogression by body weight (BW) and blood pressure (BP) assessments.By the 10th week of treatment MS was developed. After sacrifice, alongwith the progression markers of MS, we also studied oxidative markers inblood and in adipose tissue, in abdominal white adipose tissue (WAT) andinterscapular brown adipose tissue (BAT). We evaluated lipid peroxidationby TBARs determination and the oxidative status by glutathion levels(GSSG/GSH). We also evaluated adipose tissue composition modificationin MS rats.Results: Fructose treatment induced MS: it increased body weight (BW),systolic blood pressure (BP) and blood concentration of triglycerides,cholesterol, LDL-c, glucose, insulin and leptin but not that of lactate. Melatoninsignificantly counteracted the changes in BW and systolic BP inSM rats (50 days): BW (g) C) 393,2 ±17,8; F) 481,4 ±25; FM) 391,2±33,3;M) 366±40,2 and BP (mmHg): C) 102 ± 8; F) 129 ± 6; FM) 103 ± 4; M)100 ± 8. Melatonin also decreased glycemia even in untreated animals: C)107,5 ±6.3 vs. M) 91,8±3,8. Melatonin also improved glucose tolerance inMS animals. Melatonin was able to prevent the changes in insulinemia,leptinemia,plasma LDL-c, triglyceride and cholesterol, and the restof evaluated parameters. Particularly, melatonin increased BAT mass(expressed as a percentage of WAT) when compared with F or FM rats.Conclusion: These results demonstrate some benefic effects of melatoninadministration during development and establishment of the MS model,foreseeing interesting expectations about the possible utility of melatoninin the treatment of clinical MS, improving deteriorated markers in MSpatients and possibly preventing MS development in people at risk.Conflict of Interest: None Disclosed.Funding: Research relating to this abstract was funded by PIP0702 and PICT2012-0984